Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020116810 - PHARMACEUTICAL COMPOSITION, COMPRISING INHIBITORY PEPTIDE AGAINST FAS SIGNALING, FOR PREVENTION OR TREATMENT OF OBESITY, FATTY LIVER, OR STEATOHEPATITIS

Publication Number WO/2020/116810
Publication Date 11.06.2020
International Application No. PCT/KR2019/015585
International Filing Date 14.11.2019
IPC
A61K 38/08 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
08Peptides having 5 to 11 amino acids
A61K 9/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
A61P 1/16 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1Drugs for disorders of the alimentary tract or the digestive system
16for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Applicants
  • 주식회사 시그넷바이오텍 SIGNET BIOTECH CO., LTD. [KR]/[KR]
Inventors
  • 이상경 LEE, Sang-Kyung
  • 정건호 CHUNG, Kun Ho
  • 이르판울라 IRFAN, Ulla
  • 배수민 BAE, Su Min
  • 임재영 LIM, Jae Yeoung
Agents
  • 이명진 LEE, Myoung-Jin
Priority Data
10-2018-015427404.12.2018KR
Publication Language Korean (KO)
Filing Language Korean (KO)
Designated States
Title
(EN) PHARMACEUTICAL COMPOSITION, COMPRISING INHIBITORY PEPTIDE AGAINST FAS SIGNALING, FOR PREVENTION OR TREATMENT OF OBESITY, FATTY LIVER, OR STEATOHEPATITIS
(FR) COMPOSITION PHARMACEUTIQUE, COMPRENANT UN PEPTIDE INHIBITEUR CONTRE LA SIGNALISATION FAS, DESTINÉE À LA PRÉVENTION OU AU TRAITEMENT DE L’OBÉSITÉ, DU FOIE GRAS, OU DE LA STÉATOHÉPATITE
(KO) FAS 신호전달 억제용 펩티드를 포함하는 비만, 지방간 또는 지방간염의 예방 또는 치료용 약학적 조성물
Abstract
(EN)
The present invention relates to a pharmaceutical composition comprising an inhibitory peptide against Fas signaling as an active ingredient for prevention or treatment of obesity, fatty liver, or steatohepatitis. Binding specifically to Fas, which is extensively expressed in the liver and adipose tissues in an obese state, the inhibitory peptide against Fas signaling exhibits high delivery rates to inflammatory regions caused by obesity and directly inhibits the Fas signaling, which is a main inflammation signaling pathway, to inhibit an inflammatory response. Therefore, the peptide can be advantageously used for alleviating or treating obesity, fatty liver, or steatohepatitis.
(FR)
La présente invention concerne une composition pharmaceutique comprenant un peptide inhibiteur contre la signalisation Fas comme ingrédient actif destinée à la prévention ou au traitement de l’obésité, du foie gras, ou de la stéatohépatite. Par la liaison spécifiquement à Fas, qui est largement exprimée dans les tissus hépatiques et adipeux dans un état d’obésité, le peptide inhibiteur contre la signalisation Fas fait preuve de taux de libération élevés vers les régions inflammatoires causés par l’obésité et inhibe directement la signalisation Fas, qui est une voie de signalisation principale de l’inflammation, pour inhiber une réponse inflammatoire. Par conséquent, le peptide peut être avantageusement utilisé pour soulager ou traiter l’obésité, le foie gras, ou la stéatohépatite.
(KO)
본 발명은 Fas 신호전달 억제용 펩티드를 유효성분으로 포함하는 비만, 지방간 또는 지방간염의 예방 또는 치료용 약학적 조성물에 관한 것으로 상기 Fas 신호전달 억제용 펩티드는 비만시 간과 지방조직에서 많이 발현되는 Fas에 특이적으로 결합하므로 비만으로 인한 염증 부위에 대한 전달 효율이 높고, 염증의 주요 신호 전달 체계인 Fas 신호전달을 직접적으로 억제하여 염증 반응을 억제할 수 있으므로 비만, 지방간 또는 지방간염 개선, 치료 용도로 유용하게 사용될 수 있다.
Latest bibliographic data on file with the International Bureau